presented at the AIDS 2024 congress that started in Munich, Germany, yesterday – 553 patients who already had their viral load suppressed were switched to either Biktarvy or Dovato (dolutegravir ...

One of ViiV Healthcare’s two-drug HIV therapies – Dovato – has been approved in Japan, providing a new treatment option for the country’s 30,000 or so people with HIV. Dovato (dolutegravir ...

GSK posted 13% growth in HIV sales in 2024, driven by strong patient demand for long-acting injectable medicines (Cabenuva and Apretude) and Dovato.